Aadi Bioscience Q2 FYARRO sales $6.2M (+80% YoY); advancing PRECISION1 and new trials

Whitehawk Therapeutics, Inc.

2023-Q2 EPS reported -$1.23 revenue$12,069,000

FYARRO net product sales $6.2M in Q2 2023, up ~6% QoQ and 80% YoY from $3.4M.
Net loss $18.0M for Q2 2023 (vs $18.3M prior year); cash $134.9M expected to fund into 2025.
PRECISION1 trial interim analysis on 40 patients with appropriate follow-up expected before end of 2023.
Phase 2 trials in endometrial cancer (nab-sirolimus + letrozole) and NETs to initiate in Q4 2023.
First patient dosed in Phase 1/2 KRAS G12C trial with adagrasib (Mirati collaboration).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Whitehawk Therapeutics, Inc. reported the second quarter of 2023 results: revenue $6.2 million.

Period: the second quarter of 2023
Revenue: $6.2 million
Result: reported results

Exact text from the filing

Exhibit 99.1 Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update Continued growth in total revenue on FYARRO® with sales of $6.2 million for 2Q 2023 On-track for interim analysis on 40 patients in PRECISION1 trial before the end of 2023 Expanding pipeline to include programs in Endometrial Cancer and

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-028411

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.